OncoMatch/Clinical Trials/NCT07140679
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Is NCT07140679 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab for localized colon carcinoma.
Treatment: Toripalimab — This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR deficient
Deficient mismatch repair (MMR) by immunohistochemistry
Required: MSI high
microsatellite instability (MSI-H) by polymerase chain reaction (PCR) or next generation sequencing (NGS)
Disease stage
Required: Stage IIB, IIC, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — curative resection
Complete (R0) resection of pathologic stage IIB, IIC and III dMMR colon cancer 4 to 12 weeks prior to first dose of study drug
Cannot have received: neoadjuvant therapy
Neoadjuvant treatment for dMMR colon cancer
Cannot have received: immune checkpoint inhibitor
Prior treatment with any immune checkpoint inhibitor
Lab requirements
Blood counts
ANC ≥ 1,500 /mcL; Platelets ≥ 100,000 / mcL; Hemoglobin ≥ 9 g/dL or ≥ 5.0 mmol/L (transfusion allowed to obtain adequate hemoglobin level)
Kidney function
Creatinine ≤ 1.5 x ULN or measured or calculated creatinine clearance ≥ 40 mL/min for patient with creatinine levels > 1.5 x institutional ULN (GFR can also be used in place of creatinine or creatinine clearance)
Liver function
Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN
ANC ≥ 1,500 /mcL; Platelets ≥ 100,000 / mcL; Hemoglobin ≥ 9 g/dL or ≥ 5.0 mmol/L; Creatinine ≤ 1.5 x ULN or measured or calculated creatinine clearance ≥ 40 mL/min for patient with creatinine levels > 1.5 x institutional ULN (GFR can also be used in place of creatinine or creatinine clearance); Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory Decatur Hospital · Atlanta, Georgia
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
- Emory Johns Creek Hospital · Johns Creek, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify